Answers are grounded in this paper and cite their sources.
Potential risks of the ASFV-G-∆I177L vaccine strain can be managed effectively within structured vaccination strategies.
In response to the recent publication on safety concerns related to “ASFV-G-∆I177L” by van den Born et al. (2025), we emphasize the need for a thorough, context-specific risk assessment before drawing conclusions about the general field use of the ASFV-G-∆I177L vaccine strain. While valid safety concerns were raised, historical precedents highlight that potential risks, including reversion or recombination, can be managed effectively within structured vaccination strategies.
No takes yet. Share an insight, caveat, or question.
Blome et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: